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Abstract
Every day, critical care physicians around the world face the same
challenge of the optimal timing of antimicrobial administration:
when to start and when to stop antibiotics. Duration of antibiotic
therapy for sepsis is mostly based on expert opinion, but its
reduction is arguably the most promising approach to decrease
emergence and selection of antibiotic resistance. The study by
Hochreiter and colleagues presents another piece of evidence
suggesting that procalcitonin may indeed be a valuable diagnostic
parameter to guide antibiotic treatment duration, despite the
ongoing controversy about the diagnostic accuracy of pro-
calcitonin.
In the previous issue of Critical Care, Hochreiter and
colleagues presented another piece of evidence suggesting
that procalcitonin (PCT) may indeed be a valuable diagnostic
parameter to guide antibiotic treatment duration [1].
Misuse of antimicrobial agents has been a long-lasting prob-
lem in intensive care units (ICUs). Drivers of inappropriate
prescribing include diagnostic uncertainty, lack of knowledge,
unavailability of microbiologic support or infectious disease
specialists, pharmaceutical marketing pressure, and the
overarching fear of missing a life-threatening infection. Every
day, critical care physicians around the world face the same
challenge of the optimal timing of antimicrobial administration:
when to start and when to stop antibiotics.
The duration of antibiotic therapy for sepsis is mostly based
on expert opinion [2], but its reduction is arguably the most
promising approach to decrease emergence and selection of
antibiotic resistance. During the past 10 years, great
progress has been made to decrease the antibiotic treatment
duration for various types of infections, including community-
acquired pneumonia and ventilator-associated pneumonia, by
implementing fixed 8-day stopping rules [3,4]. A more tailored
approach could be the use of algorithms based on the
longitudinal course of biomarkers to facilitate individual
decision-making and choose the right moment for dis-
continuation of antibiotic therapy.
At the current moment, PCT represents the best studied
biomarker for guiding antibiotic treatment duration in the
inhospital setting. Several randomized clinical trials investi-
gating the diagnostic performance and clinical effectiveness
of PCT have been published within the past 5 years or are
currently submitted for publication [5-11]; however, few of
them included a sufficient number of patients with severe
sepsis and septic shock. In several of these studies, ICU
admission was considered an acceptable criterion to overrule
the PCT-based algorithm and initiate antibiotic therapy
despite low PCT levels. Nobre and colleagues have shown
recently that the application of an algorithm based on PCT
levels allowed significant shortening of the duration of
antibiotic therapy and of the ICU stay in critically ill patients
with life-threatening infections, without apparent harm to
patients [10].
In their article, Hochreiter and colleagues published the
English translation of another randomized clinical trial of
critically ill patients with different types of infections [1],
confirming the study findings by Nobre and colleagues [10].
The original version of the Critical Care article has already
been published in German in a peer-reviewed journal [12]
and the analysis of a slightly different subgroup of patients
has also been reported previously [13]. The major finding of
these three articles is almost identical and relates to the
reduction of the average antibiotic treatment duration and
length of ICU stay by about 2 days.
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The study by Hochreiter and colleagues was larger than
previously published PCT trials conducted in the ICU setting.
Some issues, however, warrant further comment. First,
although it is likely that the reduction effect was mainly
caused by the study intervention (PCT algorithm), it remains
unclear in how many cases the PCT algorithm was forced
into action by the study physicians or was overruled by the
physicians in charge.
Second, the precise microbiologic etiology of the causative
organisms and the documented relapse rate, secondary
infections or other complications such as reoperations were
not mentioned. It is conceivable that several cases of
pneumonia or peritonitis were bacteremic or had a more
complicated course, leading to potential antibiotic underuse
and/or reintroduction at a latter time point. Given the
heterogeneity of the included patients and infectious
syndromes, a uniform 8-day antibiotic course for the control
group might not reflect the standard of care for all indications.
Indeed, it was different from the treatment approach for the
control group in the previously reported subgroup analysis by
the same authors, where ‘treatment was discontinued
according to clinical signs and empiric rules’ [13].
Third, the study methods do not explain how the clinicians
were blinded to the PCT values in the control arm, in order to
avoid a spillover effect. How investigators were blinded for
outcome assessment to avoid differential misclassification
bias is also not described.
Fourth, the investigators used an insensitive PCT assay, which
has been replaced in many settings by a more sensitive assay,
considered more suitable for guiding antibiotic treatment
decisions and for determining treatment-stopping rules [14].
Finally, it would have been interesting to know whether PCT is
now implemented in their ICU as a routine parameter for the
daily follow-up and how this practice influences real-life
treatment decisions, outside a controlled study setting. There is
potential for PCT overuse, as with all diagnostic tools,
increasing expenditures due to the still-high costs of this test
and unforeseen adverse consequences if used indiscriminately.
Despite these limitations, the study by Hochreiter and
colleagues presents another piece of evidence suggesting that
PCT may indeed be a valuable diagnostic parameter to guide
antibiotic treatment duration. Seven randomized clinical trials
about the diagnostic effectiveness of PCT have currently been
completed [5-11], and several more are being conducted in
different parts of the world, according to international trial
registers (http://clinicaltrials.gov/ct2/results?term=procalcitonin).
Preliminary data from some of these trials are available and
confirm the safety and efficacy of PCT guidance.
In summary, all these data from randomized clinical trials are
good news for ICU physicians, despite the ongoing
controversy about the diagnostic accuracy of PCT [15,16].
Clearly, we need even better diagnostic decision support
tools if we want to help clinicians in their daily struggle for
improving antibiotic treatment decisions.
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